Research
Hormonal
Short-chain fatty acids (SCFAs) produced by gut microbiota fermentation activate G-protein coupled receptors (FFAR2/FFAR3), leading to increased secretion of GLP-1 and PYY, which improves insulin secretion and energy expenditure.
Eating prebiotic fibers (like inulin, resistant starch) feeds gut bacteria that produce SCFAs. These SCFAs signal your body to release hormones (GLP-1, PYY) that help regulate blood sugar and increase energy expenditure. This is a natural way to support metabolic health through diet.
GoodSupportsHIGH confidence
FFAR2 and FFAR3 stimulate the release of GLP-1 and peptide YY (PYY), which improve insulin secretion... SCFA-induced FFAR3 activation resulted in increased heart rate and energy expenditure through sympathetic activation.
Why this rating
The paper cites multiple studies on receptor function and hormone secretion in animal models.
Source
Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders
Ji Youn Yoo et al. · Nutrients · 2016
DOI 10.3390/nu8030173
narrative_reviewCited 339×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Administration of probiotics and prebiotics ameliorates metabolic disorders, including type 2 diabetes (T2DM) and cardiovascular disease (CVD), by modulating gut microbiota composition to stimulate insulin signaling and lower cholesterol.Moderate
- Certain probiotic strains (e.g., Lactobacillus plantarum PH04, Bifidobacterium Bb-12) significantly reduce total cholesterol, LDL-cholesterol, and triglycerides in hypercholesterolemic individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →